Detalles de la búsqueda
1.
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.
Schizophr Res
; 106(2-3): 315-9, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18835519
2.
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Psychiatry Res
; 159(1-2): 250-3, 2008 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-18374423
3.
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
Schizophr Res
; 93(1-3): 99-108, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17490862
4.
The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.
Schizophr Res
; 126(1-3): 93-102, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21071179
5.
Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.
Schizophr Res
; 121(1-3): 213-7, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20591628
6.
Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Schizophr Res
; 113(1): 19-26, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19515536
Resultados
1 -
6
de 6
1
Próxima >
>>